secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001654954-22-015284
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Q3 net loss $3.4M; cash $8.0M; 95 TAEUS scans YTD, De Novo submission near
--------------------------------------------------------------------------------

- Net loss $3.4 million ($0.05 per share) vs $2.7 million loss ($0.06) in Q3 2021.
- Cash and equivalents $8.0 million as of Sept 30, 2022; operating expenses rose to $3.4M from $2.7M.
- Nearly doubled TAEUS scans to 95 YTD; collecting final data for FDA De Novo submission for liver device.
- Expanded IP portfolio to 56 issued patents; eight new patents added in Q3.
- Management reiterates cash sufficient to fund through key milestones including European commercialization and U.S. regulatory submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/0001654954-22-015284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-015284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer